CUE vs FAST · rev $9.3M vs P/E 43, rev $7.55B
Cue Biopharma (CUE) versus Fastenal Company (FAST) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Fastenal Company (FAST) is a industrial distribution company listed on US.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported FAST revenue for 2024-12-31 was $7.55B. Net income was $1.15B. Revenue was up 2.7% from 2023-12-31 to 2024-12-31. FAST currently screens at market cap $49.48B and trailing P/E 43.1.
CUE currently screens at market cap $59.5M. FAST currently screens at market cap $49.48B and trailing P/E 43.1.
Not investment advice. Open the CUE and FAST stock pages for the full models.
Not investment advice.